⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25414922 | 1.00 | — | — | |
| SCHEMBL24105124 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL20510082 | 0.98 | CES2 (0.32) | — | |
| Hydrochloric Acid SCHEMBL27139535 | 0.98 | CES2 (0.32) | — | |
| SCHEMBL9967707 | 0.80 | — | — | |
| SCHEMBL9403603 | 0.76 | — | — | |
| SCHEMBL26561372 | 0.74 | — | — | |
| SCHEMBL23241792 | 0.74 | — | — | |
| SCHEMBL5216289 | 0.71 | CES2 (0.30) | — | |
| SCHEMBL13759869 | 0.71 | CES2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12419962-B2 | Quinazolines, pharmaceutical compositions, and therapeutic applications | BIOTHERYX, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-116648250-B | Novel quinazoline derivatives as SOS1 inhibitors and uses thereof | 韩美药品株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | disclosed |
| CN-117715642-A | Heterocyclic compounds and methods of use | 薛定谔公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240067613-A1 | NOVEL QUINAZOLINE DERIVATIVES AS SOS1 INHIBITORS AND USE THEREOF | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4269395-A1 | NOVEL QUINAZOLINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF | Hanmi Pharmaceutical Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116669738-A | Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022028506-A1 | SOS1 INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREFOR | 北京泰德制药股份有限公司 | 2022-02-10 | — | — | WO | disclosed |
| US-20110086860-A1 | COMPOUND | KIMURA TEIJI | 2011-04-14 | — | — | US | disclosed |
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7667041-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |